The Indian diabetes diagnosis and therapeutics market are anticipated to grow at a CAGR of 7% during the forecast period. The major factor driving the growth of the Indian diabetes diagnosis and therapeutics market during the forecast period is the rising prevalence of the geriatric population in the country. According to the National Commission on Population 2020 report, it was estimated that there will be nearly 138 million elderly persons in India in 2021 which will comprise 67 million males and 71 million females. Additionally, as per the same source, the growth rate of the elderly population is higher than that of the general population.
Get Free Sample link @ https://www.omrglobal.com/request-sample/indian-diabetes-diagnosis-and-treatment-market
Moreover, the growth of the market is attributed to the strategies such as new launches, partnerships, mergers, and acquisitions by key players in the market.
- In January 2022, Novo Nordisk India announced the launch of a first-of-its-kind diabetes treatment oral medication semaglutide in India. Semaglutide is a GLP-1 receptor analog (GLP-1 RA) one of the drug classes to treat diabetes
- In October 2021, Glenmark Pharmaceuticals Ltd launched a fixed-dose combination (FDC) drug for the management of Type 2 diabetes in India.
- In July 2021, Novo Nordisk developed and launched two anti-diabetes medications from its global portfolio in India in 2022. The two medications include different formulations of Semiglutide or a glucagon-like peptide-1 (GLP-1) molecule and Rybelsus, an incretin mimic in a pill form. Rybelsus is used to improve the control of blood sugar in adult patients with type 2 diabetes.
Full report of Indian Diabetes Diagnosis and Therapeutics Market available @ https://www.omrglobal.com/industry-reports/indian-diabetes-diagnosis-and-treatment-market
Market Coverage
Segment Covered-
- By Disease Type
- By Drug Type
- By Device Type
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- Elli Lilly and Co., Merck & Co., Inc., Novartis International AG, Pfizer Inc., and Glenmark Pharmaceuticals Ltd., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Indian Diabetes Diagnosis and Therapeutics Market Report by Segment
By Disease Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational
By Drug Type
- Oral anti-diabetic Drugs
- Non-Insulin Injectable drugs
- Combination Drugs
By Device Type
- Blood Glucose Monitoring Devices
- Blood Glucose Strips
- Insulin devices
- Others
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/indian-diabetes-diagnosis-and-treatment-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
